采用扩展基因分型检测高级别宫颈上皮内瘤变:Onclarity试验纵向阶段的表现数据
Onclarity宫颈癌筛查试验纵向阶段随访3年,评估扩展基因分型(xGT)筛查策略的总体效能。基线纳入29,513名≥25岁女性,HPV阴性女性3年≥CIN3累积发病风险为0.15%,HPV及细胞学双阴性为0.12%。与基于HPV16/18的原发筛查相比,HPV16/18/31立即阴道镜加xGT分流的风险筛查策略≥CIN3敏感性更高(79.2% vs 72.3%),阴道镜/≥CIN3比值更低(9.2 vs 11.2)。
要点
- HPV阴性女性3年≥CIN3累积发病风险为0.15%,与HPV及细胞学双阴性(0.12%)提供相似的三年无病保证。
- HPV16的基线和3年≥CIN3累积发病风险最高,其次为HPV31和HPV18。
- 基因型别持续感染至少1年较同期的基因型非持续、清除或新发感染增加≥CIN3风险。
核心结论
- HPV阴性结果在三年随访中提供的无病保证与阴性联合检测结果相同。
- xGT有助于风险筛查和持续感染追踪,可在不过度增加阴道镜操作的情况下优化筛查中的疾病检出。
研究设计与样本
- Onclarity宫颈癌筛查试验纵向阶段,基线29,513名≥25岁女性具有可评估细胞学和有效高危HPV结果。
- 细胞学为未明确意义的不典型鳞状细胞或更严重,或HPV检测阳性的女性转诊阴道镜/活检。
- 未达到研究终点(治疗≥CIN2)的参与者进入纵向阶段,方案与基线相同。
主要发现
- HPV阴性女性3年≥CIN3累积发病风险为0.15%[95%CI:0.06,0.26];HPV及细胞学双阴性女性为0.12%[95%CI:0.03,0.23]。
- HPV16的基线和3年≥CIN3累积发病风险最高,其次为HPV31和HPV18。
- 基因型别持续至少1年较基因型非持续、清除或同期新发感染增加xGT结果的≥CIN3风险。
- HPV16/18/31立即阴道镜加xGT分流策略较基于HPV16/18的原发筛查≥CIN3敏感性更高(79.2% vs 72.3%;相对差异6.9[95%CI:3.3,10.4]),阴道镜/≥CIN3比值更低(9.2 vs 11.2;相对差异-1.9[95%CI:-2.6,-1.3])。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Onclarity cervical cancer screening trial was designed to establish the clinical validity of the Onclarity HPV assay for extended genotyping (xGT) during detection of high-grade cervical neoplasia grades 2 or 3 (≥CIN2 or ≥CIN3). Here, three-year follow up data is presented to evaluate the overall efficacy of these screening strategies, compared to the baseline data. METHODS: At baseline 29,513 women, ≥25 years, had evaluable cytology and valid high-risk HPV results. Women with atypical squamous cells-undetermined significance or worse cytology or a positive HPV test were referred for colposcopy/biopsy. Participants that did not reach the study end point (treatment for ≥CIN2) continued into the longitudinal phase that included the same protocol as baseline. RESULTS: The three-year cumulative incident risk (CIR) for ≥CIN3 in HPV-negative women was 0.15% [95%CI: 0.06, 0.26] and for HPV- and cytology-negative women was 0.12% [95% CI: 0.03,0.23]. HPV16 carried the highest baseline and three-year ≥CIN3 CIR, followed by HPV31 and HPV18. At least one year of genotype-specific persistence increased ≥CIN3 risk for xGT results compared to genotype non-persistence, HPV clearance, or new infection over the same time period. Risk-based screening with immediate colposcopy for HPV16/18/31 and further xGT triage resulted in better ≥CIN3 sensitivity (79.2% versus 72.3%; relative difference of 6.9 [95%CI: 3.3, 10.4]) and a lower colposcopy/≥CIN3 ratio (9.2 versus 11.2; relative difference of -1.9 [95%CI: -2.6, -1.3]) when compared to primary HPV16/18-based screening. CONCLUSIONS: An HPV-negative result offers the same assurance of no disease over three years of follow up as that offered by a negative co-testing result. xGT facilitates risk-based screening and persistence tracking and can help optimize disease detection during screening without excessive colposcopic procedures.
引用
- Stoler MH, Wright TC, Parvu V, et al. Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial. Gynecol Oncol. 2023. PMID: 36682092. doi:10.1016/j.ygyno.2023.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。